Atara Biotherapeutics (ATRA) Capital Expenditures (2014 - 2024)
Atara Biotherapeutics' (ATRA) quarterly Capital Expenditures came in at $90000.0 in Q4 2024, up 104.05% YoY from $44106.7 in Q1 2024, and down 42.31% on a QoQ basis from $156000.0 in Q2 2024.
Atara Biotherapeutics (ATRA) Capital Expenditures (2014 - 2024) Analysis & Trends
Atara Biotherapeutics (ATRA) has 11 years of Capital Expenditures data on file, last reported at $90000.0 in Q4 2024.
- Quarterly Capital Expenditures rose 104.05% year-over-year to $90000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $90000.0 (up 104.36% YoY) and the FY2024 annual result came in at $246000.0, up 123.59% from the prior year.
- Capital Expenditures slipped to $90000.0 in Q4 2024, from $156000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $2.6 million in Q1 2022 to a low of -$2.5 million in Q2 2022.
- A 5-year average of $328666.7 and a median of $281000.0 in 2021 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2020 — Capital Expenditures surged 742.72% — and 2023, when it tumbled 8646.15%.
- Tracing ATRA's Capital Expenditures over 5 years: stood at $601000.0 in 2020, then sank by 53.24% to $281000.0 in 2021, then slumped by 90.75% to $26000.0 in 2022, then plunged by 8646.15% to -$2.2 million in 2023, then surged by 104.05% to $90000.0 in 2024.
- The last three Capital Expenditures figures came in at $90000.0 (Q4 2024), $156000.0 (Q2 2024), and -$2.2 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 90,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Dec 31, 2023 | -2.22 Mn |
| Dec 31, 2023 | -2.22 Mn |
| Sep 30, 2023 | 281,000.00 |
| Sep 30, 2023 | 281,000.00 |
| Jun 30, 2023 | 704,000.00 |
| Jun 30, 2023 | 704,000.00 |
| Mar 31, 2023 | 194,000.00 |
| Mar 31, 2023 | 194,000.00 |
| Dec 31, 2022 | 26,000.00 |
| Dec 31, 2022 | 26,000.00 |
| Sep 30, 2022 | -97,000.00 |
| Sep 30, 2022 | -97,000.00 |
| Jun 30, 2022 | -2.47 Mn |
| Jun 30, 2022 | -2.47 Mn |
| Mar 31, 2022 | 2.61 Mn |
| Mar 31, 2022 | 2.61 Mn |